drugset / Trial / NCT02598440
A Study of Ibandronate (Bonviva) in Patients With Post-Menopausal Osteoporosis
RandomizedCrossoverOpen-labelTreatment
Summary
This study will evaluate participant-reported preference for either ibandronate or a comparator drug in women with postmenopausal osteoporosis. The anticipated time of study treatment is 6 months, and the target sample size is 338 individuals.
Timeline
- Start
- 2004-03
- Primary completion
- 2005-05
- Completion
- 2005-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Alendronic Acid | Small molecule | 70 mg | Oral |
| Subject | Ibandronate | Other / unclassified | 150 mg | Oral |